Recursion and Exscientia Shareholders Approve the Proposed Combination

Core Viewpoint - Recursion and Exscientia have received overwhelming shareholder approval for their proposed business combination, which is expected to close on November 20, 2024 [1][2][3] Group 1: Transaction Details - The transaction is anticipated to close on November 20, 2024, pending customary closing conditions [2] - Recursion will host an update call on the closing date, broadcasting via multiple platforms [2] Group 2: Company Profiles - Recursion is a clinical stage TechBio company focused on industrializing drug discovery through its Recursion Operating System, which utilizes extensive datasets and machine-learning algorithms [4] - Exscientia is a technology-driven drug design company that integrates AI and automation to create effective medicines more efficiently, with a focus on oncology and other therapeutic areas [6] Group 3: Leadership and Future Outlook - Chris Gibson, Co-Founder and CEO of Recursion, will continue as CEO of the combined entity, emphasizing the integration of both companies' capabilities to enhance drug discovery [3] - The combination aims to leverage Recursion's biological and chemical exploration with Exscientia's molecular design to accelerate drug development [3]